Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2023 | The difficulties of MRD detection in DLBCL

Mark Roschewski • 6 Sep 2023
SOHO 2023
Diffuse Large B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma

Mark Roschewski, MD, National Institutes of Health, Bethesda, MD, discusses why measurable residual disease (MRD) detection has not yet been broadly applied in the field of diffuse large B-cell lymphoma (DLBCL), due to the need to measure cell-free DNA. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Mark Roschewski

1:21
Response-adapted therapy with copanlisib and rituximab for previously untreated FL
Mark Roschewski • 8 Dec 2023
1:17
Ibrutinib & chemotherapy (TEDDI-R) in the treatment of secondary CNS lymphoma
Mark Roschewski • 8 Dec 2023
1:36
Analyzing circulating tumor DNA to determine remission in patients with lymphoma
Mark Roschewski • 8 Dec 2023
1:28
The remaining hurdles for using ctDNA in lymphoma
Mark Roschewski • 6 Sep 2023

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals